hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06333873 id: P22-09 briefTitle: Impact of Age-related Macular Degeneration on Daily Living Activitie acronym: AMDAY overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-06 date: 2029-06 date: 2024-03-27 date: 2024-03-27 name: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts class: OTHER briefSummary: The complex and variable course of age-related diseases makes it all the more necessary to carry out personalised, reasoning-based examinations to improve the personalised assessment and management of AMD. However, functional assessment of AMD is most often based solely on visual acuity, and classifications of AMD are based solely on structural markers. There is therefore a need to improve the detection and functional assessment of this vision-threatening eye disease, by complementing and extending the standard assessments of clinical outcomes (COA) conditions: Age-Related Macular Degeneration studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, longitudinal, interventional, exploratory, non-randomised, single-centre study including healthy volunteers and patients with AMD primaryPurpose: OTHER masking: NONE count: 120 type: ESTIMATED name: patient-reported outcome measure: Validity of criteria measure: Validity of content measure: Reproducibility of results sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333860 id: M24-541 briefTitle: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) overallStatus: NOT_YET_RECRUITING date: 2024-05-07 date: 2025-03-24 date: 2026-03-31 date: 2024-03-27 date: 2024-03-27 name: AbbVie class: INDUSTRY briefSummary: Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly.
This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. conditions: Moderate Plaque Psoriasis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 336 type: ESTIMATED name: Risankizumab name: Deucravacitinib measure: Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) measure: Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from Baseline measure: Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR). measure: Period A: Percentage of Participants Achieving 100% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 100) measure: Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 with at least 2-grade improvement from Baseline measure: Period B: Percentage of Participants Achieving 100% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 100) among participants in the ITT_B_NR Population measure: Period B: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 with at least 2-grade improvement from Baselineamong participants in the ITT_B_NR Population. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333847 id: K2023-059 briefTitle: Is Multimorbidity a Source of Non-response Bias in Patients With Spinal Pain? - A Pilot Study overallStatus: ENROLLING_BY_INVITATION date: 2023-06-01 date: 2024-04-20 date: 2024-04-20 date: 2024-03-27 date: 2024-03-27 name: Jacob Christiansen Gandløse class: OTHER name: Aalborg Municipality name: Aalborg University name: Aalborg University Hospital briefSummary: The purpose of this study is to investigate whether the number of chronic diseases, the treatment burden resulting from multimorbidity, and health-related quality of life contribute to non-response bias in individuals with chronic back pain. Data is collected from patients at Aalborg University Hospital's Rheumatology Department through electronic means and medical records. The statistical analyses consist of two wave analyses, where we examine differences between patients who respond to invitations to participate in the study based on their response patterns; whether they respond after the first, second, or third invitation. Based on baseline data, a one-way ANOVA is conducted to identify any between-group differences in the aforementioned factors, followed by a repeated measures ANOVA to assess if there are differences between the groups over time. Finally, statistical tests are also performed to examine differences in age and gender distribution between those who complete the questionnaires at baseline compared to those who do not respond to the invitation to participate. conditions: Back Pain conditions: Low Back Pain conditions: Neck Pain conditions: Comorbidities and Coexisting Conditions studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: Multimorbidity Treatment Burden Questionnaire (MTBQ). measure: Health-related quality of life (EQ-5D-5L) measure: Brief Pain Inventory - Short form measure: Insomnia Severity Index measure: Patient Health Questionnaire measure: Generalized Anxiety Disorder measure: Work ability score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aalborg University Hospital city: Aalborg zip: 9000 country: Denmark lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06333821 id: BPL-Nim-CC-3003 briefTitle: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2030-04-01 date: 2030-04-01 date: 2024-03-27 date: 2024-03-27 name: Biotech Pharmaceutical Co., Ltd. class: OTHER briefSummary: The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma.
The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival. conditions: Cervical Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a multicenter prospective, randomized, double-blind, placebo-controlled phase III trial primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: This study is double-blind and will blind both the investigator and the subjects. All participants in the study (including data managers and biostatisticians) will be unaware of treatment assignment (except blind statisticians). whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 460 type: ESTIMATED name: Nimotuzumab name: Cisplatin name: External Beam Radiotherapy (EBRT) name: Brachytherapy name: placebo for Nimotuzumab measure: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed Blinded Independent Central Review (BICR) measure: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by by the Investigator measure: 3-,5-Year Overall Survival (OS) measure: 3-,5-Year Disease Free Survival(DFS) measure: 3-,5-Year Locoregional Recurrence-Free Survival(LRRFS) measure: 3-,5-Year Distant Metastasis-free Survival (DMFS) measure: Tumor Regression Rate(TRR) measure: Complete Response Rate measure: Complete Response Rate measure: Objective Response Rate measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score measure: Incidence of Treatment-Emergent Adverse Events sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333808 id: GS-US-621-6290 id: 2023-510022-33 type: OTHER domain: European Medicines Agency briefTitle: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy acronym: ARTISTRY-2 overallStatus: RECRUITING date: 2024-03-25 date: 2025-12 date: 2029-12 date: 2024-03-27 date: 2024-04-17 name: Gilead Sciences class: INDUSTRY briefSummary: The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH).
The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH. conditions: HIV-1-infection studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized in parallel in one of two treatment groups during the Blinded Phase. Participants in both treatment groups will be given the option to continue BIC/LEN FDC treatment during the Open-Label Phase. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 546 type: ESTIMATED name: Bictegravir name: Lenacapavir name: B/F/TAF name: Placebo to match B/F/TAF name: Placebo to match BIC/LEN measure: Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm measure: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm measure: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48 measure: Treatment Group 1: Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm measure: Treatment Group 1: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 96 as Determined by US FDA-defined Snapshot Algorithm measure: Treatment Group 1: Change from Baseline in CD4 Cell Count at Week 96 measure: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) through Week 48 measure: Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs through Week 96 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ruane Medical and Clinical Research Institute status: RECRUITING city: Los Angeles state: California zip: 90036 country: United States lat: 34.05223 lon: -118.24368 facility: Therafirst Medical Center status: RECRUITING city: Fort Lauderdale state: Florida zip: 33308 country: United States lat: 26.12231 lon: -80.14338 facility: Midway Immunology and Research Center status: RECRUITING city: Fort Pierce state: Florida zip: 34982 country: United States lat: 27.44671 lon: -80.32561 facility: Infectious Disease Specialists of Atlanta status: RECRUITING city: Decatur state: Georgia zip: 30033 country: United States lat: 33.77483 lon: -84.29631 facility: Southhampton Community Healthcare, Inc. status: RECRUITING city: Saint Louis state: Missouri zip: 63139 country: United States lat: 38.62727 lon: -90.19789 facility: South Jersey Infectious Disease status: RECRUITING city: Somers Point state: New Jersey zip: 08244 country: United States lat: 39.31762 lon: -74.5946 facility: The Crofoot research Center, INC. status: RECRUITING city: Houston state: Texas zip: 77098 country: United States lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06333795 id: 1-10-72-131-23 briefTitle: Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis acronym: FaeMiCue overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-31 date: 2025-12-31 date: 2024-03-27 date: 2024-03-27 name: University of Aarhus class: OTHER briefSummary: This clinical trial aims to assess the safety and effectiveness of faecal Microbiota Transplantation (FMT) in improving chronic diarrhea symptoms among patients with systemic sclerosis. conditions: Diarrhea conditions: Systemic Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will undergo 2 interventions. For the first intervention participants are randomised 1:1 for either Active FMT or placebo For the second intervention, all participants receive active treatment. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The study is blinded throughout the active study period, both the patient and investigator are blinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Faecal Microbiota Transplantation (FMT) name: Placebo measure: Number of adverse events (AE) severity grade 2 or more assessed by CTCAE v5.0. during the first week after intervention (FMT or placebo). measure: Patient-reported treatment outcome on symptoms measure: Patient-reported measures from the schedule of side effects and telephone call 1 week after each intervention. measure: Patient-reported outcomes from questionnaires. measure: Patient-reported outcomes from questionnaires. measure: Patient-reported outcomes from questionnaires. measure: Patient-reported overall symptom burden measure: Objective measures from the wireless motility capsule. measure: Objective measures from the wireless motility capsule. measure: Objective measures from the wireless motility capsule. measure: Objective measures from the wireless motility capsule. measure: Objective measures from the low-dose CT scan. measure: Breath Test measure: Faecal microbiota composition measure: Faecal-calprotectin measure: Blood plasma proteomics measure: Blood plasma Fibrosis markers measure: Blood parameters measure: Health-related Quality of life measure: Patient perception of FMT treatment satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aarhus University Hospital city: Aarhus country: Denmark lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06333782 id: 2023-EU-GEN-01 id: 2023-A02012-43 type: OTHER domain: ANSM briefTitle: Evaluation of the Safety and Efficacy of Hyaluronic Acid Injection in Labia Majora Augmentation overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2025-07-01 date: 2025-07-01 date: 2024-03-27 date: 2024-04-02 name: Bioscience Cosmetics SL class: INDUSTRY name: Eurofins briefSummary: The goal of this interventional clinical investigation using Genefill Contour® CE marked device outside of its indication is to compare with other hyaluronic acid device already marketed for labia majora augmentation in women with labia majora hypotrophy/atrophy.
An ancillary study would be conducted in a cohort of participants evaluating the increase in volume and distance between labia after HA injection conditions: Vulvar Atrophy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants would be randomized on two groups: Genefill Contour or comparator (Desirial Plus) at a ratio 1:1 primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single blind whoMasked: PARTICIPANT count: 110 type: ESTIMATED name: Experimental- Genefill Contour® name: Marketed comparator - Desirial®Plus measure: Mean of number of occurred ADEs (Adverse device effects) measure: Global Aesthetic Improvement Scale (GAIS) assessment by investigator measure: Global Aesthetic Improvement Scale (GAIS) assessment by participant measure: Patient (Atrophy/Hypotrophy) symptoms measure: Sexual function Assessment, The Female Sexual Function Index (FSFI) measure: Patient´s satisfaction measure: Pain during injection-Visual Analogical Scale (VAS) measure: Adverse Events collection (Global safety during the study period) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cabinet renaissance city: Levallois-Perret state: Paris zip: 92300 country: France name: Massimo Gianfermi, MD role: CONTACT lat: 48.89389 lon: 2.28864 facility: Palais Flore city: Lyon zip: 69006 country: France name: Johanna Gratadour, MD role: CONTACT lat: 45.74848 lon: 4.84669 facility: Medical Center "Tu sie leczy" city: Gdańsk state: Gdansk country: Poland name: Katarzyna Kopacz-Petranyuk, MD role: CONTACT lat: 54.35205 lon: 18.64637 hasResults: False
nctId: NCT06333769 id: CATIMOR briefTitle: A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-01 date: 2026-12-01 date: 2024-03-27 date: 2024-03-27 name: Fujian Cancer Hospital class: OTHER_GOV briefSummary: To explore the complete response (CR) rate of improved short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer conditions: Mid-low Rectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 31 type: ESTIMATED name: Short-course Radiotherapy name: Tislelizumab name: capecitabine name: Oxaliplatin measure: complete response (CR) rate measure: 3y-DFS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333756 id: YM110099E briefTitle: Effects of Muscle Strengthening and Fatigue on Activities in Cortex and Muscle acronym: YM110099E overallStatus: COMPLETED date: 2021-05-01 date: 2022-04-30 date: 2022-08-01 date: 2024-03-27 date: 2024-03-27 name: National Yang Ming University class: OTHER briefSummary: We will explored the effect of cross education training on different cortex functional connectivity, cortex and muscle functional connectivity, and maximal voluntary contraction.
Healthy participants receive cross education training of the elbow flexor (12 rep./set, 3sets, 60%MVC, 180°/s, eccentric).Maximal voluntary contraction, electroencephalogram and electromyogram will record during cross education tasks to determine the effects of cross education training on cortical network and muscle functional connectivity conditions: Healthy Adults studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Parallel Assignment primaryPurpose: BASIC_SCIENCE masking: NONE count: 40 type: ACTUAL name: Cross education measure: Corticocortical coherence measure: Corticomuscular coherence measure: Maximal voluntary contraction sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: National Yang-Ming University city: Taipei zip: 112 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06333743 id: ZhuLan briefTitle: Laser Ablation in the Treatment of High-grade Cervical Lesions overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-12 date: 2026-05 date: 2024-03-27 date: 2024-03-27 name: Peking Union Medical College Hospital class: OTHER name: Obstetrics & Gynecology Hospital of Fudan University briefSummary: Cervical laser ablation is an effective, minimally invasive treatment with a low incidence of perinatal complications and minimal impact on fertility. Research has confirmed that laser ablation treatment of cervical HSIL (including CIN2 and CIN3) is effective and feasible and is useful for young CIN3 patients who wish to get pregnant in the future. There have been no randomized clinical trials of laser ablation therapy for cervical HSIL in Chinese women. This study focuses on the application of laser ablation in the treatment of cervical HSIL, explores the efficacy, feasibility, and safety of laser ablation in the treatment of cervical HSIL, and strives to promote the reasonable application of laser ablation in the treatment of cervical HSIL. conditions: High-Grade Squamous Intraepithelial Lesions studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 308 type: ESTIMATED name: laser ablation name: LEEP or Conization measure: the rate of HSIL recurrence measure: the satisfaction with the treatment measure: the length of the cervix measure: Psychological state change related to the treatment sex: FEMALE maximumAge: 40 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06333730 id: PMC briefTitle: Comparison of Anesthetic Efficacy of Mental Nerve Block Versus Inferior Alveolar Nerve Block in Mandibular Anterior Teeth and Premolars in Symptomatic Irreversible Pulpitis overallStatus: RECRUITING date: 2024-04-01 date: 2024-05-30 date: 2024-06-20 date: 2024-03-27 date: 2024-03-27 name: Prime Foundation class: OTHER briefSummary: Symptomatic irreversible pulpitis is a painful condition that requires anesthesia to perform effective dental procedures. The mental nerve block and inferior alveolar nerve block are two commonly used techniques for achieving anesthesia in the mandibular teeth.
Both techniques will use 2% lidocaine and adrenaline 1:80,000. Age, gender, and the efficacy of anesthesia will be recorded in both groups. The chi-square test will be used for comparison. conditions: Symptomatic Irreversible Pulpitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 96 type: ESTIMATED name: inferior alveolar nerve block name: mental nerve block measure: COMPARISON OF ANESTHETIC EFFICACY OF MENTAL NERVE BLOCK VERSUS INFERIOR ALVEOLAR NERVE BLOCK IN MANDIBULAR ANTERIORS TEETH AND PREMOLARS IN SYMPTOMATIC IRREVERSIBLE PULPITIS sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Peshawar Dental College status: RECRUITING city: Peshawar state: Khyber Pakhtunkhwa zip: 25000 country: Pakistan name: Prof. Dr. Iftikhar Akbar, FCPS, CHIPE role: CONTACT phone: 00923479368676 email: driftikhar156@hotmail.com name: Marghalara Noor, BDS role: CONTACT phone: 00923359631393 email: marghalaranoor96@gmail.com name: Saifa Rashad, BDS role: SUB_INVESTIGATOR lat: 34.008 lon: 71.57849 hasResults: False